Super Precision medicine. New drugs have been developed to selectively target with more significant efficacy than before.

Lately, news articles related to anticancer agents have frequently covered keywords related to genetic mutations, including MET, RET, ALK, EGFR, and ROS1. Customized treatments are becoming available, where effective treatments can be provided depending on the patient's particular genetic mutations.

Pharmaceuticals targeting HER2, ALK, and EGFR have been developed, and they show superior effects in patients with particular conditions. Lately, pharmaceuticals have been developed selectively targeting difficult-to-develop gene mutations, such as ROS, NTRK, and RET.